Prostaglandin D2 inhibits the proliferation of human malignant tumor cells.
The cytotoxic effect of prostaglandin (PG) D2, PGE1 and PGF2 alpha was examined on human osteosarcoma cells (KSu cell line) in vitro, and PGD2 was most effective. DNA, RNA and protein syntheses of KSu cells were also found to be inhibited by PGD2 at a concentration of 5 micrograms/ml. Furthermore, the proliferation of various human malignant tumor cells was inhibited by PGD2 without exception so far. These results suggest that PGD2 shows an anti-neoplastic effect on a variety of human malignant tumor cells.
D000970:Antineoplastic Agents; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D015237:Dinoprost; D015232:Dinoprostone; D006801:Humans; D009363:Neoplasm Proteins / Q000096:biosynthesis; D009369:Neoplasms / Q000188:drug therapy*; D009696:Nucleic Acids / Q000096:biosynthesis; D012516:Osteosarcoma / Q000188:drug therapy* / Q000378:metabolism; D015230:Prostaglandin D2; D011457:Prostaglandins D / Q000627:therapeutic use*; D011458:Prostaglandins E / Q000627:therapeutic use; D011460:Prostaglandins F / Q000627:therapeutic use
D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D009696:Nucleic Acids; D011457:Prostaglandins D; D011458:Prostaglandins E; D011460:Prostaglandins F; D015237:Dinoprost; D015232:Dinoprostone; D015230:Prostaglandin D2